Publicaciones en colaboración con investigadores/as de Merck Institute for Science Education (5)

2022

  1. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

    New England Journal of Medicine, Vol. 386, Núm. 6, pp. 556-567

  2. Pembrolizumab in Triple-Negative Breast Cancer. Reply

    The New England journal of medicine

  3. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

    New England Journal of Medicine, Vol. 387, Núm. 3, pp. 217-226

2020

  1. Pembrolizumab for early triple-negative breast cancer

    New England Journal of Medicine, Vol. 382, Núm. 9, pp. 810-821

  2. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

    The Lancet, Vol. 396, Núm. 10265, pp. 1817-1828